Just to add, I still have to agree with the CHM holders, if any of these 2, IMU or CHM, has a chance for a big revival, then it would be CHM. Their AML NK-cell trial is fast moving and got frontline treatment as its goal. And CDH17 attacks solid Gastric cancer types directly. From that point, if any of CHM's platforms succeeds then it should become more valuable than IMU's.
Again, sometimes it is hard to accept the reality, isn't it?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
-0.001(6.67%) |
Mkt cap ! $104.5M | |||
| Open | High | Low | Value | Volume |
| 1.5¢ | 1.5¢ | 1.3¢ | $255.7K | 18.24M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 65 | 18692454 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 4515891 | 5 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |